Y. Iriagac

Efficacy and safety of trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer: a single center study

Yakup İriağaç, E. Çavdar, Kubilay Karaboyun, 2022, Iberoamerican Journal of Medicine.

Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?

E. Çavdar, Kubilay Karaboyun, E. Şeber, 2023, Supportive Care in Cancer.

Soluble B7H3 level in breast cancer and its relationship with clinicopathological variables and T cell infiltration

Yakup İriağaç, E. Çavdar, Kubilay Karaboyun, 2022, Contemporary oncology.

PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study.

E. Çavdar, Kubilay Karaboyun, E. Şeber, 2023, Journal of geriatric oncology.

A logarithmic model for hormone receptor-positive and breast cancer patients treated with neoadjuvant chemotherapy

E. Çavdar, Kubilay Karaboyun, E. Şeber, 2023, Revista da Associacao Medica Brasileira.

Comparison of three equations for estimating glomerular filtration rate as predictors of cisplatin-related acute kidney injury in lung cancer patients with normal renal function

Yakup İriağaç, E. Çavdar, Kubilay Karaboyun, 2024, Journal of cancer research and therapeutics.

Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer

A. Arıcan, D. Aydın, M. Eryılmaz, 2024, BMC cancer.

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.

U. Demirci, Ozlem Dogan, A. Erdoğan, 2023, Future oncology.

The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey

U. Demirci, O. Dizdar, E. Goker, 2023, Medicine.